R-CHOP regimen can significantly decrease the risk of disease relapse and progression in patients with non-germinal center B-cell subtype diffuse large B-cell lymphoma

To further explore the role of rituximab when added to the CHOP-like regimen in the treatment of immunohistochemically defined non-germinal center B-cell subtype (non-GCB) diffuse large B-cell lymphoma (DLBCL), 159 newly diagnosed DLBCL patients were studied retrospectively based on the immunohistoc...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Xiao-Hui, Li, Bo, Yang, Sheng, Lu, Ning, Zhang, Xun, Zou, Shuang-Mei, Li, Ye-Xiong, Song, Yong-Wen, Zheng, Shan, Dong, Mei, Zhou, Sheng-Yu, Yang, Jian-Liang, Liu, Peng, Zhang, Chang-Gong, Qin, Yan, Feng, Feng-Yi, Shi, Yuan-Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sun Yat-sen University Cancer Center 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777489/
https://www.ncbi.nlm.nih.gov/pubmed/22640627
http://dx.doi.org/10.5732/cjc.011.10420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777489/
https://www.ncbi.nlm.nih.gov/pubmed/22640627
http://dx.doi.org/10.5732/cjc.011.10420

Ejemplares similares